CLAIMS

1. Use of a polypeptide or a protein in the manufacture of a medicament for treating pain, wherein the medicament is to be administered to relieve pain in a mammal in need thereof, and wherein the polypeptide or the protein is a RANK/RANKL antagonist, and wherein the pain is osteoarthritis pain and the RANK/RANKL antagonist is denosumab.

2. The use of claim 1, wherein, within a period of about six months, about 0.1 mg/kg to about 20 mg/kg of denosumab is to be administered to the mammal.

3. The use of claim 1, wherein, within a period of about six months, about 0.5 mg/kg to about 2 mg/kg of denosumab is to be administered to the mammal.

4. The use of claim 3, wherein the denosumab is to be administered once every six months.

5. The use of claim 1, wherein the mammal is a human being.

6. The use of claim 1, wherein the pain is associated with osteoarthritis of the knee.

7. The use of claim 1, wherein the osteoarthritis affects a knee or hip.

8. The use of claim 1, wherein the osteoarthritis affects an elbow, a shoulder, a wrist, or a finger.

9. Use of a polypeptide or a protein in the manufacture of a medicament for treating pain, wherein the medicament is to be administered to relieve pain in a mammal in need thereof, and wherein the polypeptide or the protein is a RANK/RANKL antagonist, and wherein the pain is complex regional pain syndrome and the RANK/RANKL antagonist is denosumab.

10. The use of claim 9, wherein, within a period of about six months, about 0.1 mg/kg to about 20 mg/kg of denosumab is to be administered to the mammal.

11. The use of claim 9, wherein, within a period of about six months, about 0.5 mg/kg to about 2 mg/kg of denosumab is to be administered to the mammal.

12. The use of claim 11, wherein the denosumab is to be administered once every six months.

13. The use of claim 9, wherein the mammal is a human being.

14. Use of a polypeptide or a protein in the manufacture of a medicament for treating pain, wherein the medicament is to be administered to relieve pain in a mammal in need thereof, and wherein the polypeptide or the protein is a RANK/RANKL antagonist, and wherein the pain is low back pain and the RANK/RANKL antagonist is denosumab.

15. The use of claim 14, wherein the pain is chronic low back pain.

16. The use of claim 14, wherein the low back pain is associated with Modic changes.

17. The use of claim 14, wherein, within a period of about six months, about 0.1 mg/kg to about 20 mg/kg of denosumab is to be administered to the mammal.

18. The use of claim 14, wherein, within a period of about six months, about 0.5 mg/kg to about 2 mg/kg of denosumab is to be administered to the mammal.

19. The use of claim 18, wherein the denosumab is to be administered once every six months.

20. The use of claim 14, wherein the mammal is a human being.